Reviewed by Dr Sarah Mitchell, PhD · Editorial Board
Ozempic in the UK — patient guide
Ozempic is the Novo Nordisk semaglutide brand licensed for type 2 diabetes. It is the same active ingredient as Wegovy but a different product, different licensed indication, different doses, and a different supply chain. This guide explains how the UK supply works and why off-label weight-loss prescribing of Ozempic has become a problem.
What Ozempic is
Ozempic is semaglutide presented for the treatment of type 2 diabetes. It is supplied as a pre-filled injection pen and given subcutaneously once weekly. Its mechanism (GLP-1 receptor agonism) produces weight loss as a secondary effect, which is why it has been heavily prescribed off-label.
UK licensed use vs off-label use
Ozempic’s UK marketing authorisation is for type 2 diabetes. The same active ingredient is separately licensed as Wegovy for weight management. UK prescribing guidance is to:
- Use Ozempic for type 2 diabetes (its licensed indication).
- Use Wegovy for weight management.
- Use Mounjaro (tirzepatide) for either, where appropriate.
Off-label Ozempic prescribing for weight loss is lawful where a GMC-registered prescriber takes documented personal clinical responsibility, but it has increasingly been discouraged because it pulls supply away from diabetes patients.
Dose strengths
Ozempic is available in 0.25 mg, 0.5 mg, 1 mg, and 2 mg strengths. The 0.25 mg dose is a 4-week starter, not therapeutic for glycaemic control. Maintenance is 0.5 mg, 1 mg, or 2 mg depending on glycaemic response.
Note: the Ozempic dose range (max 2 mg) is lower than Wegovy (max 2.4 mg). Patients sometimes ask to “just up the Ozempic dose” for weight-loss effect; the licensed guidance does not support pushing past 2 mg on Ozempic.
Supply pressure
Sustained off-label demand has left Ozempic supply tight, intermittent, or rationed at various points. The MHRA and professional bodies have issued repeated guidance asking clinicians to:
- Prioritise patients with type 2 diabetes for Ozempic.
- Direct weight-management patients to Wegovy or Mounjaro.
- Counsel diabetes patients about possible supply interruption and what to do if Ozempic is unavailable.
See GLP-1 shortages for the current picture and what patients should do.
Counterfeit Ozempic
The MHRA has flagged counterfeit Ozempic reaching UK patients via unlicensed online supply. Real Ozempic ships in Novo Nordisk branded packaging with a UK Patient Information Leaflet, a recognisable Novo Nordisk pen, and matching batch/expiry on box and pen. See fake Ozempic pens.
Red-flag claims
If you see wording like this on a seller, clinic, or social-media advert, treat it as a warning sign rather than a benefit.
“Ozempic for weight loss — no diabetes diagnosis needed”
Off-label prescribing of Ozempic for weight management is being actively discouraged. Wegovy is the licensed product for that indication.
“Bulk Ozempic — UK shipping, no prescription”
POM supply without a prescription. Same unlicensed-supply pattern that has produced the counterfeit Ozempic seizures.
“Cheap Ozempic from an EU pharmacy”
Cross-border POM supply into the UK without a UK prescription is unlawful. Counterfeit Ozempic has reached UK patients via this route.
“Push your Ozempic dose to 3 mg for faster results”
Outside the Ozempic licence and beyond what the available data supports. Higher doses are studied in Wegovy, which has a different licence.
Sources & further reading
- MHRA — gov.uk
- MHRA Drug Safety Update — gov.uk
- Yellow Card — yellowcard.mhra.gov.uk
- Report a problem with a medicine or medical device — gov.uk
- NHS — type 2 diabetes treatment — nhs.uk
- Human Medicines Regulations 2012 — legislation.gov.uk